Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:16:15.028Z.
Calculation as of: 2026-10-06T14:16:15.028Z.
Quote observation: 2026-10-06T14:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8c517f571e23d8c9640577b72a0d01a1674ca2fb527f0620093024032568825b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$5.10B
Price/OCF Ratio
18.00
TTM Avg
16.87
3Y Avg
25.21
5Y Avg
27.56
Market Cap
$5.04B
Price/OCF Ratio
N/A
TTM Avg
27.45
3Y Avg
27.45
5Y Avg
27.45
Market Cap
$5.32B
Price/OCF Ratio
N/A
TTM Avg
11.41
3Y Avg
54.55
5Y Avg
54.55
Market Cap
$4.84B
Price/OCF Ratio
106.62
TTM Avg
302.47
3Y Avg
302.47
5Y Avg
302.47
Market Cap
$4.81B
Price/OCF Ratio
N/A
TTM Avg
198.10
3Y Avg
199.02
5Y Avg
199.02
Market Cap
$5.52B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | $5.16B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 18.00 | 16.87 | 25.21 | 27.56 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.04B | N/A | 27.45 | 27.45 | 27.45 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.32B | N/A | 11.41 | 54.55 | 54.55 |
| Doximity, Inc. (DOCS)vs › | $5.33B | 17.39 | 20.94 | 34.29 | 45.54 |
| Erasca, Inc. (ERAS)vs › | $4.93B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.84B | 106.62 | 302.47 | 302.47 | 302.47 |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.81B | N/A | 198.10 | 199.02 | 199.02 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | N/A | N/A | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.72B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
